Table 1.
SARS-CoV-2 pseudoviruses
| Virus Protein | Packaging System | Application | Reference |
|---|---|---|---|
| SARS-CoV-2 Spike | pCMVdeltaR8.91, pLAS2w.RFP-C.Pneo, pMD.G-S | Neutralization antibody assay | 22 |
| SARS-CoV-2 Spike | HDM-IDTSpike-fixK, HDM-Hgpm2, HDM-tat1b, pRC-CMV-Rev1b, pHAGE-CMV-Luc2-IRES-ZsGreen-W | Neutralization antibody assay, Main protease inhibitors evaluation | 50, 51 |
| SARS-CoV-2 Spike | psPAX2, pLenti-GFP, pCMV14-3×Flag-S | Virus entry and immune cross-reactivity, identifying monoclonal antibodies | 23, 52 |
| SARS-CoV-2 Spike (D614/G614) | pHAGE-fullEF1α-ZsGreen-IRES-Puro(R), Lentiviral proteins encoding plasmids (Tat, Rev and Gag/Pol), pS (D614/G614) | MEK inhibitors evaluation | 53 |
| SARS-CoV-2 Spike | pcDNA3.1-SARS2-Spike, psPAX2, pUltra-hot | Brain organoids infection | 49 |
| SARS-CoV-2 Spike | pNL4-3.Luc.R-E-, pcDNA3.1-SARS-CoV-2-S or pCMV3-SARS-CoV-2-S | Neutralization antibody assay and entry inhibition test, entry inhibitors identification, membrane fusion inhibitors evaluation | 15, 19-21 |
| SARS-CoV-2 Spike | pNL4-3/KFS, pSARS-CoV-2-S | Virus assembly | 18 |
| SARS-CoV-2 Spike | pCMV-MLVgag-pol, pTG-Luc, pCAGGS-SARS-CoV-2-S | Virus entry and cross-neutralizing antibody assay | 28, 54 |
| SARS-CoV-2 Spike | SV-Psi--Env--MLV, L-LUC-SN, pSARS-CoV-2-S | Neutralization assay | 27 |
| SARS-CoV-2 Spike | rVSV∆G-G, pSARS-CoV-2-S | Entry and neutralization assay, vaccine | 17, 35, 36, 48, 55, 56 |
| SARS-CoV-2 ORF1ab, N, E | psPAX, PCDH-ORF1ab-N-E, pMD2G; MS2-ORF1ab, MS2-N, MS2-E | Comparing commercial SARS-CoV-2 nucleic acid detection reagents | 24 |
| SARS-CoV-2 Spike | NS1-deleted influenza A virus, pSARS-CoV-2-S | vaccine | 39 |
| SARS-CoV-2 Spike | adenovirus type 5, adenovirus type 26, ChAdOx, SARS-CoV-2-S | vaccine | 40-42 |